BPC 157: The peptide with big claims and scant evidence STAT The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News FDA Drug Recalls and Warnings: Recalls for Compounded Semaglutide and Tirzepatide, Wegovy; Facility Warning Letters MedShadow Foundation